REATA PHARMACEUTICALS CEO J Huff's 2020 pay rises 15% to $6.4M
REATA PHARMACEUTICALS reports 2020 executive compensation
By ExecPay News
Published: April 30, 2021
REATA PHARMACEUTICALS reported fiscal year 2020 executive compensation information on April 30, 2021.
In 2020, five executives at REATA PHARMACEUTICALS received on average a compensation package of $4.6M, a 4% increase compared to previous year.
Average pay of disclosed executives at REATA PHARMACEUTICALS
J. Warren Huff, Chief Executive Officer, received $6.4M in total, which increased by 15% compared to 2019. 84% of Huff's compensation, or $5.3M, was in option awards. Huff also received $414K in bonus, $636K in salary, as well as $5K in other compensation.
For fiscal year 2020, the median employee pay was $568,580 at REATA PHARMACEUTICALS. Therefore, the ratio of J. Warren Huff's pay to the median employee pay was 11 to one.
Manmeet S. Soni, Chief Financial Officer, received a compensation package of $4.5M, which decreased by 65% compared to previous year. 75% of the compensation package, or $3.3M, was in option awards.
Colin J. Meyer, Chief Research and Development Officer and Executive Vice President, earned $4.2M in 2020, a 94% increase compared to previous year.
Michael D. Wortley, Chief Legal Officer, received $4M in 2020, which increases by 95% compared to 2019.
Dawn C. Bir, Chief Commercial Officer and Executive Vice President, earned $3.9M in 2020, a 96% increase compared to previous year.
Related executives
J Huff
REATA PHARMACEUTICALS
Chief Executive Officer
Manmeet Soni
REATA PHARMACEUTICALS
Chief Financial Officer
Dawn Bir
REATA PHARMACEUTICALS
Chief Commercial Officer and Executive Vice President
Colin Meyer
REATA PHARMACEUTICALS
Chief Innovation Officer and Executive Vice President
Michael Wortley
REATA PHARMACEUTICALS
Chief Legal Officer
You may also like
Source: SEC filing on April 30, 2021.